Published in Arch Intern Med on April 24, 2006
Type 2 diabetes as an inflammatory disease. Nat Rev Immunol (2011) 8.30
Adipokines and insulin resistance. Mol Med (2008) 2.97
Inflammatory mechanisms in the regulation of insulin resistance. Mol Med (2008) 2.71
"Control" laboratory rodents are metabolically morbid: why it matters. Proc Natl Acad Sci U S A (2010) 2.50
Obesity, inflammation, and liver cancer. J Hepatol (2011) 2.09
Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci (2014) 2.03
Inflammation, insulin resistance, and diabetes--Mendelian randomization using CRP haplotypes points upstream. PLoS Med (2008) 1.95
Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care (2010) 1.86
Elimination of the NLRP3-ASC inflammasome protects against chronic obesity-induced pancreatic damage. Endocrinology (2011) 1.82
Adipokines and the peripheral and neural control of energy balance. Mol Endocrinol (2008) 1.66
TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab (2010) 1.48
Inflammation as a Link between Obesity and Metabolic Syndrome. J Nutr Metab (2012) 1.47
Nuclear factor κB-inducing kinase activation as a mechanism of pancreatic β cell failure in obesity. J Exp Med (2015) 1.39
Blocking interleukin-1β in acute and chronic autoinflammatory diseases. J Intern Med (2011) 1.35
Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol (2012) 1.32
Getting away from glucose: fanning the flames of obesity-induced inflammation. Nat Med (2009) 1.28
Obesity and upper airway control during sleep. J Appl Physiol (1985) (2009) 1.21
Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum (2010) 1.21
Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome. Am J Physiol Endocrinol Metab (2007) 1.17
Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis. Arthritis Res Ther (2012) 1.09
Targeting inflammation in diabetes: Newer therapeutic options. World J Diabetes (2014) 1.08
Association of body fat with C-reactive protein in rheumatoid arthritis. Arthritis Rheum (2008) 1.06
Adipokines - removing road blocks to obesity and diabetes therapy. Mol Metab (2014) 1.04
Gene silencing in adipose tissue macrophages regulates whole-body metabolism in obese mice. Proc Natl Acad Sci U S A (2013) 1.04
Therapeutic approaches to target inflammation in type 2 diabetes. Clin Chem (2010) 1.03
Recent advances in obesity-induced inflammation and insulin resistance. Front Endocrinol (Lausanne) (2013) 1.02
Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era. AIDS (2007) 1.01
Innate immune activation in obesity. Mol Aspects Med (2012) 0.99
Relation of body composition to body mass index in HIV-infected patients with metabolic abnormalities. J Acquir Immune Defic Syndr (2008) 0.98
Chronic TNF-α neutralization does not improve insulin resistance or endothelial function in "healthy" men with metabolic syndrome. Mol Med (2010) 0.95
Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns. Arch Med Sci (2015) 0.93
Macrophages, fat, and the emergence of immunometabolism. J Clin Invest (2013) 0.93
Innate and ozone-induced airway hyperresponsiveness in obese mice: role of TNF-α. Am J Physiol Lung Cell Mol Physiol (2015) 0.92
Reduced adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B. Endocrinology (2009) 0.91
microRNAs as a new mechanism regulating adipose tissue inflammation in obesity and as a novel therapeutic strategy in the metabolic syndrome. J Immunol Res (2014) 0.89
Adipokines and hepatic insulin resistance. J Diabetes Res (2013) 0.88
Molecular targets related to inflammation and insulin resistance and potential interventions. J Biomed Biotechnol (2012) 0.88
Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis. Clin Transl Immunology (2016) 0.84
Paradoxical glucose-sensitizing yet proinflammatory effects of acute ASP administration in mice. Mediators Inflamm (2013) 0.82
Metabolic syndrome in rheumatoid arthritis. Maedica (Buchar) (2012) 0.82
Decreased respiratory quotient in relation to resting energy expenditure in HIV-infected and noninfected subjects. Metabolism (2009) 0.81
Interleukin-1 antagonists and other cytokine blockade strategies for type 1 diabetes. Rev Diabet Stud (2012) 0.81
Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. J Clin Invest (2017) 0.81
Diabetes treatment in 2025: can scientific advances keep pace with prevalence? Ther Adv Endocrinol Metab (2012) 0.79
Effects of TNF-alpha antagonism on E-selectin in obese subjects with metabolic dysregulation. Clin Endocrinol (Oxf) (2010) 0.79
Factors related to HIV-associated neurocognitive impairment differ with age. J Neurovirol (2014) 0.78
Fast recovery with etanercept in patients affected by polymyalgia rheumatica and decompensated diabetes: a case-series study. Clin Rheumatol (2008) 0.78
The acute effects of low-dose TNF-α on glucose metabolism and β-cell function in humans. Mediators Inflamm (2014) 0.78
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. Dermatol Ther (Heidelb) (2012) 0.76
Hyporesponsiveness to the anti-inflammatory action of interleukin-10 in type 2 diabetes. Sci Rep (2016) 0.76
Plasma levels of inflammatory cytokines in adult Nigerians with the metabolic syndrome. Niger Med J (2016) 0.75
Regulation of LYRM1 gene expression by free fatty acids, adipokines, and rosiglitazone in 3T3-L1 adipocytes. Exp Diabetes Res (2011) 0.75
Identification of dual-tropic HIV-1 using evolved neural networks. Biosystems (2015) 0.75
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med (1998) 46.95
Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA (2002) 25.68
Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science (1993) 25.54
Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation (2004) 20.67
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA (2002) 18.43
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med (2000) 18.04
Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation (2000) 8.17
Plasma adiponectin levels and risk of myocardial infarction in men. JAMA (2004) 7.46
Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation (2000) 7.37
C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol (1999) 7.15
C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation (2003) 6.99
Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation (2000) 6.96
Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care (2004) 6.68
Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab (1997) 5.84
Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med (1995) 5.24
Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation (2001) 4.82
The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care (2005) 4.38
Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol (2002) 3.66
Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation (2000) 3.66
The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest (1995) 3.39
Assessment of abdominal fat content by computed tomography. Am J Clin Nutr (1982) 3.22
Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest (1994) 3.16
Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol (2002) 3.03
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum (2003) 2.91
Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care (2005) 2.50
Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation (2002) 2.45
Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation (2002) 2.40
Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-alpha antagonist. J Clin Endocrinol Metab (2004) 2.11
Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res (2005) 2.06
Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes (1996) 1.91
Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab (2003) 1.75
A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Insulin Resistance Atherosclerosis Study. Diabetes (1994) 1.73
Soluble tumour necrosis factor receptor treatment does not affect raised transforming growth factor beta levels in rheumatoid arthritis. Ann Rheum Dis (2002) 1.71
Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab (2004) 1.55
Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-alpha. Am J Physiol Endocrinol Metab (2004) 1.51
Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors. Am J Physiol Endocrinol Metab (2004) 1.27
No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab (2000) 1.25
High resolution ultrasound detects a decrease in pannus vascularisation of small finger joints in patients with rheumatoid arthritis receiving treatment with soluble tumour necrosis factor alpha receptor (etanercept). Ann Rheum Dis (2002) 1.20
A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study. Ann Rheum Dis (2001) 1.01
Regulation of transcription factor mRNA accumulation during 3T3-L1 preadipocyte differentiation by tumour necrosis factor-alpha. J Mol Endocrinol (1992) 1.00
Etanercept in psoriatic arthritis. Expert Opin Biol Ther (2003) 0.79
Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab (2007) 9.77
Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab (2008) 3.64
Arterial inflammation in patients with HIV. JAMA (2012) 3.42
How accurate are assays for 25-hydroxyvitamin D? Data from the international vitamin D external quality assessment scheme. Clin Chem (2004) 3.30
Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS (2010) 3.27
Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum (2007) 3.14
Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr (2009) 2.99
Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr (2012) 2.56
State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation (2008) 2.17
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS (2005) 2.16
Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis (2013) 2.15
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr (2002) 1.98
Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab (2007) 1.97
Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system. J Acquir Immune Defic Syndr (2012) 1.85
Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr (2010) 1.70
Medical findings in outpatients with anorexia nervosa. Arch Intern Med (2005) 1.69
Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS (2012) 1.63
Risk factors for early-onset and late-onset hepatocellular carcinoma in Asian immigrants with hepatitis B in the United States. Am J Gastroenterol (2011) 1.61
Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA (2008) 1.58
Reduced growth hormone secretion in obesity is associated with smaller LDL and HDL particle size. Clin Endocrinol (Oxf) (2012) 1.51
TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab (2010) 1.48
Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384. Clin Infect Dis (2007) 1.47
Determinants of skeletal loss and recovery in anorexia nervosa. J Clin Endocrinol Metab (2006) 1.27
Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr (2007) 1.27
Relationship between neck circumference and cardiometabolic parameters in HIV-infected and non-HIV-infected adults. Diabetes Care (2011) 1.26
Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. AIDS (2013) 1.23
Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS (2006) 1.19
Mitochondrial function and insulin resistance in overweight and normal-weight children. J Clin Endocrinol Metab (2009) 1.19
Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS (2004) 1.18
Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome. Am J Physiol Endocrinol Metab (2007) 1.17
Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects. Clin Endocrinol (Oxf) (2012) 1.17
Effects of obesity, body composition, and adiponectin on carotid intima-media thickness in healthy women. J Clin Endocrinol Metab (2006) 1.16
Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA (2004) 1.16
Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr (2006) 1.12
Altered miRNA processing disrupts brown/white adipocyte determination and associates with lipodystrophy. J Clin Invest (2014) 1.12
Reduced growth hormone secretion is associated with increased carotid intima-media thickness in obesity. J Clin Endocrinol Metab (2009) 1.11
Growth hormone (GH) responses to GH-releasing hormone-arginine testing in human immunodeficiency virus lipodystrophy. J Clin Endocrinol Metab (2004) 1.08
Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS (2009) 1.06
Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab (2010) 1.03
Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. J Clin Endocrinol Metab (2003) 1.02
Skeletal muscle phosphocreatine recovery after submaximal exercise in children and young and middle-aged adults. J Clin Endocrinol Metab (2010) 1.01
Relation of body composition to body mass index in HIV-infected patients with metabolic abnormalities. J Acquir Immune Defic Syndr (2008) 0.98
Metabolic and cardiovascular complications in HIV-infected patients: new challenges for a new age. J Infect Dis (2012) 0.98
Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients. Eur J Endocrinol (2014) 0.98
Genetic analysis implicates resistin in HIV lipodystrophy. AIDS (2008) 0.96
Clinical, cognitive, and social characteristics of a sample of neuroleptic-naive persons with schizotypal personality disorder. Schizophr Res (2005) 0.94
Effects of aging and smoking on carotid intima-media thickness in HIV-infection. AIDS (2013) 0.93
Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy. Am J Physiol Endocrinol Metab (2003) 0.92
Body composition and metabolic changes in HIV-infected patients. J Infect Dis (2012) 0.92
Effect of body mass index on peak growth hormone response to provocative testing in children with short stature. J Clin Endocrinol Metab (2009) 0.91
Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab (2012) 0.90
Increased epicardial adipose tissue volume in HIV-infected men and relationships to body composition and metabolic parameters. AIDS (2010) 0.90
Associations of cardiovascular risk factors with two surrogate markers of subclinical atherosclerosis: endothelial function and carotid intima media thickness. Atherosclerosis (2011) 0.88
Cardiovascular disease in HIV-positive patients. AIDS (2005) 0.88
Receptor activator of nuclear factor-κB ligand (RANKL) and its relationship to coronary atherosclerosis in HIV patients. J Acquir Immune Defic Syndr (2012) 0.88
HIV-specific immune dysregulation and atherosclerosis. Curr HIV/AIDS Rep (2012) 0.87
The association of growth hormone parameters with skeletal muscle phosphocreatine recovery in adult men. J Clin Endocrinol Metab (2010) 0.87
Inflammation, immune activation, and cardiovascular disease in HIV. AIDS (2016) 0.87
Differences in peak bone mass in women of European and South Asian origin can be explained by differences in body size. Osteoporos Int (2005) 0.86
Immune dysregulation and vascular risk in HIV-infected patients: implications for clinical care. J Infect Dis (2011) 0.86
Endocrine and metabolic effects of physiologic r-metHuLeptin administration during acute caloric deprivation in normal-weight women. J Clin Endocrinol Metab (2004) 0.85
Plaque burden in HIV-infected patients is associated with serum intestinal microbiota-generated trimethylamine. AIDS (2015) 0.83
Nocturnal ghrelin pulsatility and response to growth hormone secretagogues in healthy men. Am J Physiol Endocrinol Metab (2004) 0.83
Acute regulation of adiponectin by free fatty acids. Metabolism (2004) 0.83
Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis (2012) 0.82
Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. AIDS (2011) 0.82
Estrogen sulfotransferase is expressed in subcutaneous adipose tissue of obese humans in association with TNF-alpha and SOCS3. J Clin Endocrinol Metab (2011) 0.82
Characterization of leptin pulse dynamics and relationship to fat mass, growth hormone, cortisol, and insulin. Am J Physiol Endocrinol Metab (2003) 0.82
Decreased respiratory quotient in relation to resting energy expenditure in HIV-infected and noninfected subjects. Metabolism (2009) 0.81
Absence of polycystic ovary syndrome features in human immunodeficiency virus-infected women despite significant hyperinsulinemia and truncal adiposity. J Clin Endocrinol Metab (2005) 0.80
UK Food Standards Agency Optimal Nutrition Status Workshop: environmental factors that affect bone health throughout life. Br J Nutr (2003) 0.80
Adrenal function in HIV infection. Curr Opin Endocrinol Diabetes Obes (2010) 0.80
Pathologic and clinical features of pituitary adenomas showing TSH immunoreactivity. Pituitary (2013) 0.80
Effects of growth hormone-releasing hormone on bone turnover in human immunodeficiency virus-infected men with fat accumulation. J Clin Endocrinol Metab (2004) 0.79
Ciclosporin therapy is associated with minimal changes in calcium metabolism in dogs with atopic dermatitis. Vet Dermatol (2012) 0.79
Vascular dysfunction and cardiovascular complications. Curr Opin HIV AIDS (2007) 0.79
Increased aldosterone among HIV-infected women with visceral fat accumulation. AIDS (2009) 0.79
The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH. J Clin Endocrinol Metab (2013) 0.79
Skeletal muscle mitochondrial function is associated with longitudinal growth velocity in children and adolescents. J Clin Endocrinol Metab (2011) 0.79
Prednisolone therapy for atopic dermatitis is less effective in dogs with lower pretreatment serum 25-hydroxyvitamin D concentrations. Vet Dermatol (2011) 0.79
GH/GHRH axis in HIV lipodystrophy. Pituitary (2009) 0.79
Effects of TNF-alpha antagonism on E-selectin in obese subjects with metabolic dysregulation. Clin Endocrinol (Oxf) (2010) 0.79
Imaging atherosclerotic burden and inflammation: insights into the spectrum of atherosclerotic disease in HIV. J Nucl Cardiol (2014) 0.78
Reciprocal changes in endogenous ghrelin and growth hormone during fasting in healthy women. Am J Physiol Endocrinol Metab (2005) 0.77
The relationship between reduced testosterone, stimulated growth hormone secretion and increased carotid intima-media thickness in obese men. Clin Endocrinol (Oxf) (2010) 0.77
Effects of lifestyle modification and metformin on irisin and FGF21 among HIV-infected subjects with the metabolic syndrome. Clin Endocrinol (Oxf) (2014) 0.77
Adipose compartmentalization and insulin resistance among obese HIV-infected women: the role of intermuscular adipose tissue. Am J Clin Nutr (2007) 0.77
Relationship of peak growth hormone to cardiovascular parameters, waist circumference, lipids and glucose in HIV-infected patients and healthy adults. Clin Endocrinol (Oxf) (2009) 0.76
Subclinical myocyte injury, fibrosis and strain in relationship to coronary plaque in asymptomatic HIV-infected individuals. AIDS (2016) 0.76
Relation of leptin pulse dynamics to fat distribution in HIV-infected patients. Am J Clin Nutr (2004) 0.76
Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV. AIDS (2017) 0.76
Increased skeletal muscle phosphocreatine recovery after sub-maximal exercise is associated with increased carotid intima-media thickness. Atherosclerosis (2010) 0.75
Corrigendum: Adipose-derived circulating miRNAs regulate gene expression in other tissues. Nature (2017) 0.75
Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS (2017) 0.75
Erratum: Vitamin D status in cats with feline immunodeficiency virus. Vet Med Sci (2016) 0.75